WHAT IS ForeSENTIA?

ForeSENTIA is a tumor profiling genetic test that can identify a spectrum of genetic alterations and genomic biomarkers, such as Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).

The information provided by ForeSENTIA can offer guidance on treatment decisions, prognostic value, and improved clinical management through precision medicine and targeted therapies.


ForeSENTIA CHARACTERISTICS

  • Option to test for clinically actionable genetic alterations, and immunotherapy biomarkers MSI and TMB in a single test
  • Testing of thoroughly selected genetic alterations and biomarkers:
    • Genes recommended by NCCN guidelines for solid tumors
    • Genes that currently serve as selection criteria in active clinical trials
    • Tumor-agnostic biomarkers
  • Guidance on available targeted therapies, including immunotherapies. Tailored therapies can reduce the risk of ineffective therapy and adverse side effects, and avoid a 'one-size-fits-all' approach.
ForeSENTIA CASE STUDIES

A 68-year-old male was diagnosed with lung adenocarcinoma


ForeSENTIA Lung (NSCLC) tumor profile panel identified:

  • 5 genetic alterations in KRAS, STK11 and ATM genes

Based on these findings, the patient was eligible for:

  • The FDA-approved drug sotorasib

In addition, the results are associated with:

  • A total of 59 clinical trials associated with the KRAS genetic alteration
  • 38 clinical trials associated with the STK11 and ATM genetic alterations

The results also demonstrated that the co-occurring of STK11 and KRAS genetic alterations will suppress the efficacy of PD-1/PD-L1 immunotherapy​ inhibitors.​

A 67-year-old female was diagnosed with stage III colorectal cancer


Pan-Cancer Plus identified MSI-high status, as well as a TMB score of 12 mut/Mb. These results are associated with:

  • 3 FDA/EMA approved immunotherapy drugs, including pembrolizumab, for colorectal cancer
  • Over 90 related clinical trials

In addition, ForeSENTIA results led to:

  • Identification of 7 genetic alterations in BRCA2, CTNNB1, RET, IDH2 and other genes

Based on these findings, the patient was eligibile for a total of:

  • 6 off-labeled drugs, including olaparib and selpercatinib
  • 11 clinical trials

The identification of the BRCA2 genetic alteration, which is of potential germline origin, can provide useful information and improved clinical management for the patient's relatives.

ForeSENTIA PANELS

The ForeSENTIA panels screen for clinically actionable genetic alterations or genomic biomarkers which can be associated with approved therapies or are the focus of ongoing clinical trials.


EXTENDED TUMOR PROFILE PANELS

These panels target mutations in an extended number of genes, and include testing for MSI via Next Generation Sequencing (NGS).

  • PAN-CANCER PLUS

    Targets all exonic regions of the genes tested, and includes TMB and MSI assessment via NGS.

    221*

  • PAN-CANCER

    Targets specific regions on the genes tested, and includes MSI assessment via NGS.

    80*

* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.

PAN-CANCER PLUS PANEL

Description

The ForeSENTIA Pan-Cancer Plus panel tests for all exonic regions in an extended number of genes and includes immunotherapy biomarkers MSI and TMB assessment via Next Generation Sequencing. Identifying the genetic alterations and genomic biomarkers that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA Pan-Cancer Plus panel to help identify the specific genetic alterations and genomic biomarkers that are associated with their tumor.

Number Of Genes Tested

221*

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA Pan-Cancer Plus panel​, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements​ or a combination of variants.

ForeSENTIA Pan-Cancer Plus Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations​ Rearrangements​
ABL1, ABL2, AKT1, AKT2, ALK, ANKRD26, APC, AR, ARAF, ASXL1, ATM, ATRX, B2M, BAP1, BARD1, BCL2, BCL6, BCOR, BCORL1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBFB, CBL, CBLB, CBLC, CCND1, CCND2, CCND3, CCNE1, CD274, CD74, CDC25C, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CIC, CSF1R, CSF3R, CTLA4, CTNNB1, CUX1, CXCR4, DCK, DDR2, DDX41, DEK, DHX15, DICER1, DNMT3A, DUSP22, EGFR, EIF1AX, EPCAM, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ESR1, ETNK1, ETV1, ETV4, ETV6, EWSR1, EZH2, FANCA, FBXW7, FGF13, FGF19, FGF2, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FRS2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HDAC2, HOXB13, HRAS, IDH1, IDH2, IKZF1, IL3, INHA, INSRR, IRF4, JAK1, JAK2, JAK3, KDM6A, KDR, KEAP1, KIT, KMT2A, KMT2C, KMT2D, KRAS, LUC7L2, MALT1, MAP2K1, MAP2K2, MAP3K1, MDM2, MECOM, MET, MLH1, MLLT3, MPL, MRE11, MSH2, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, MYH11, MYOD1, NBN, NCOA3, NF1, NF2, NFE2L2, NOTCH1, NPM1, NRAS, NRG1, NTRK1, NUP214, NUTM1, PALB2, PARP1, PBX1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PGR, PHF6, PIK3CA, PIK3CB, PIK3R1, PML, PMS2, POLD1, POLE, PPM1D, PPP2R1A, PTCH1, PTEN, PTPN11, RAD21, RAD51C, RAD51D, RAF1, RARA, RB1, RBBP6, RET, RNF43, RPS14, RUNX1, RUNX1T1, SETBP1, SF3B1, SH2B3, SLC29A1, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX10, SPOP, SRSF2, STAG2, STAT3, STAT5B, STK11, SUZ12, TCF3, TCL1A, TERT, TET2, TMPRSS2, TP53, TSC1, TSC2, U2AF1, VEGFA, VHL, WT1, XPO1, ZRSR2 1p/q19 codeletion, ATK1, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CD274, CDK4, CDKN2A, CHEK2, EGFR, ERBB2, ERBB3, ESR1, FGFR1, FGFR2, FGFR3, JAK2, KIT, KRAS, MDM2, MET, MYC, MYCN, NCOA3, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA​, PIK3CB, PTEN, RAF1, RB1, RET, SMAD4, TERT, TP53​ ALK, BRAF, CD74, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, RET, ROS1, TMPRSS2

Testing for Microsatellite Instability (MSI) and Tumor Mutational Burder (TMB) is included in the Pan-Cancer Plus panel.

PAN-CANCER PANEL​

Description

The ForeSENTIA Pan-Cancer panel tests for an extended number of genes and includes immunotherapy biomarker MSI assessment via Next Generation Sequencing. Identifying the genetic alterations and genomic biomarkers that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA pan-cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

80*

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA pan-cancer tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements​ or a combination of variants.

ForeSENTIA Pan-Cancer Panel​

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations​ Rearrangements​
AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, CIC, CTNNB1, DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FLT3, FOXA1, FOXL2, FUBP1, GATA3, GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, NBN, NF1, NPM1, NRAS, NTRK1, PALB2, PDGFRA, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, SPOP, STK11, TERT, TP53 1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 ALK, BRAF, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2

Testing for Microsatellite Instability (MSI) is included in the Pan-Cancer panel. ​


CANCER-SPECIFIC TUMOR PROFILE PANELS

These panels target specific mutations in several genes and can optionally include MSI assessment via NGS.

  • BREAST / GYNECOLOGICAL

    48

  • COLORECTAL

    34

  • GLIOMA

    22*

  • LUNG (NSCLC)

    36

  • MELANOMA

    22

  • PROSTATE

    36

* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.

BREAST/GYNECOLOGICAL PANEL​

Description

The ForeSENTIA breast/gynecological panel​ tests for numerous genetic alterations that are frequently found in gynecological tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with breast or gynecological cancer can have tumor profile testing with the ForeSENTIA breast/gynecological panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

48

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA breast/gynecological panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Breast/Gynecological Panel​

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
AKT1, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CHEK2, CTNNB1, DICER1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FOXA1, FOXL2, GATA3, KIT, KRAS, MAP3K1, MLH1, MRE11A, MSH2, MSH6 MTOR, NBN, NRAS, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, TP53 EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN, TP53 NTRK1, NTRK2, NTRK3

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.

COLORECTAL PANEL

Description

The ForeSENTIA colorectal panel​ tests for numerous genetic alterations that are frequently found in colorectal tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with colorectal cancer can have tumor profile testing with the ForeSENTIA colorectal cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

34

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA colorectal panel​, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Colorectal Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
AKT1, APC, ATM, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MLH1, MSH2, MSH6, MTOR, NRAS, NTRK1, PALB2, PDGFRA, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAF1, SMAD4, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, TP53 NTRK1, NTRK2, NTRK3

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.

LUNG (NSCLC) PANEL​

Description

The ForeSENTIA lung (NSCLC) panel tests for numerous genetic alterations that are frequently found in lung (Non Small Cell Lung Cancers – NSCLC) tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with lung (NSCLC) cancer can have tumor profile testing with the ForeSENTIA lung (NSCLC) panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

36

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA lung (NSCLC) panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Lung (NSCLC) Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
AKT1, ALK, APC, ARAF, ATM, BRAF, BRCA2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, FBXW7, JAK2, KEAP1, KRAS, MAP2K1, MET, NRAS, PDGFRA, PIK3CA, POLE, PTEN, RAF1, SMAD4, STK11, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, PIK3CA, PTEN, TP53 ALK, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.

MELANOMA PANEL

Description

The ForeSENTIA melanoma panel tests for numerous genetic alterations that are frequently found in melanomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with melanoma cancer can have tumor profile testing with the ForeSENTIA melanoma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

22

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA melanoma panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Melanoma Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
AKT1, BRAF, CTNNB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, NF1, NRAS, PIK3CA, POLE, PTEN, TP53 ERBB2, KIT, KRAS, MYC, TP53 ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.

PROSTATE PANEL

Description

The ForeSENTIA prostate panel​ tests for numerous genetic alterations that are frequently found in prostate tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with prostate cancer can have tumor profile testing with the ForeSENTIA prostate panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

36

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA prostate panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Prostate Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
AKT1, APC, AR, ATM, BARD1, BRAF, BRCA1, BRCA2, CTNNB1, CHEK2, FOXA1, MLH1, MSH2, MSH6, NRAS, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, SPOP, TP53 AR, ERBB2, FGFR1, FGFR2, FGFR3, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 NTRK1, NTRK2, NTRK3, TMPRSS2

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.

GLIOMA PANEL

Description

The ForeSENTIA glioma panel tests for numerous genetic alterations that are frequently found in gliomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with glioma cancer can have tumor profile testing with the ForeSENTIA glioma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

22*

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA glioma panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Rearrangements or a combination of variants.

ForeSENTIA Glioma Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Rearrangements
ATRX, BRAF, CIC, CTNNB1, EGFR, FUBP1, H3F3A, IDH1, IDH2, NF1, POLE, TERT, TP53 1p/19q codeletion, CDKN2A, EGFR, MET, MYC, MYCN, PTEN BRAF, FGFR3, NTRK1, NTRK2, NTRK3

Microsatellite Instability (MSI) testing can optionally be included to identify patients who would benefit from immunotherapy, and offer prognostic information.


GENE-FOCUSED PANELS

These panels target specific mutations in one or two genes.

ForeSENTIA TESTS FOR:


Genetic Alterations


Genetic alterations include Single Nucleotide Variants (SNVs), Insertions & Deletions (INDELs), Copy Number Alterations (CNAs) and Rearrangements.

They can drive tumor development in multiple types of cancer, and can be responsible for therapy resistance and cancer relapse.

Applicable for

Gene Targeted Therapies

MSI Biomarker


MSI is caused by defects in the DNA mismatch repair mechanisms, resulting in the accumulation of short repeated DNA sequences known as microsatellites, which cause genetic hypermutability.

MSI can offer prognostic and therapeutic value for patients with different types of solid tumors, including but not limited to: colorectal, endometrial, gastric, prostate and bladder cancer.

Applicable for

Immunotherapy

TMB Biomarker


TMB indicates the total number of somatic mutations found in a tumor per megabase.

Pan-Cancer Plus provides > 1Mb of genomic coverage for accurate TMB scoring. Evidence suggests that TMB can offer prognostic value for patients with solid tumors, including rare types, as well as therapeutic opportunities for TMB-high patients in a tumor-agnostic manner

Applicable for

Immunotherapy

Both MSI and TMB are genomic biomarkers that identify patients eligible for immunotherapy treatment. Although some correlation exists between the two, MSI and TMB scores are not always associated. Results for each biomarker depend on the tumor type and the underlying mechanisms and pathways involved.

Pan-Cancer Plus can assess both genomic biomarkers and provide an informative interpretation of the results, indicating the applicable approved therapies and clinical trials related to immunotherapy.


genetic alterations genomic biomarkers tested per tumor profile panel

ROBUST AND ACCURATE RESULTS

Targeted Technology

ForeSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision

Novel Bioinformatic Analysis

Multi-engine analysis incorporating innovative bioinformatic pipelines analyze the sequencing data produced. These enable accurate detection of different types of genetic alterations, even at low levels, as well as of genomic biomarkers.

High Read Depth

Specifically designed analytical methods to ensure high read depth, raising the sensitivity and specificity of the test.


WHAT WILL THE REPORT TELL ME?

The ForeSENTIA report will empower you to take informed and accurate decisions on the best clinical management of your patient. The information provided can guide you to currently approved therapies and ongoing clinical trials that are most applicable for your patient's tumor profile results


HOW TO ADMINISTER ForeSENTIA?

  • RECOMMEND ForeSENTIA TO YOUR PATIENT
  • LET THE HISTOPATHOLOGY LAB KNOW THAT ADDITIONAL TESTING WILL BE REQUIRED ON THE TISSUE BIOPSY SAMPLE
  • THE HISTOPATHOLOGY LAB WILL SEND THE TUMOR SECTIONS TO NIPD Genetics
  • THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
  • THE RESULTS WILL BE SENT TO YOU IN 2-3 WEEKS

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!